Intellipharmaceutics International Inc. IPCIQ

IPCIQ Company Overview

Intellipharmaceutics International Inc. (OTC Pink: IPCIQ) is a Canadian pharmaceutical development company focused on the research, development, and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has historically operated in the specialty pharmaceutical industry, with an emphasis on reformulations of existing drugs using proprietary drug delivery technologies intended to improve dosing profiles, patient compliance, and product lifecycle management. Public disclosures in SEC filings and Canadian regulatory documents indicate that the company’s business model centered on developing generic and branded pharmaceutical products for therapeutic areas including central nervous system disorders, pain management, and neurology.

The company’s primary revenue drivers historically included product licensing arrangements, research and development collaborations, and limited commercial pharmaceutical sales tied to approved abbreviated new drug applications (ANDAs). Intellipharmaceutics developed proprietary controlled-release technologies such as Hypermatrix and IntelliCap, which were designed to enable customized drug release profiles. Founded in Canada in the late 1980s and later publicly listed in both Canada and the United States, the company evolved from a drug delivery research organization into a specialty pharmaceutical developer pursuing U.S. FDA approvals for generic and branded formulations. Publicly available information regarding current operating scale and commercial activity is limited, and certain recent operational details are inconclusive based on available public sources.